ColchiBIND is a sterile liquid immunotherapeutic product for intravenous administration. It is employed exclusively for the treatment of colchicine toxicity and is the only specific medicinal product currently available for this purpose. Pre-clinical studies are on-going and clinical studies expected to commence in 2017.
ViperaVet has been developed for the treatment of dogs envenomed by one of the four medically important species of Vipera (adder) found throughout Western Europe. An initial clinical trial took place in the UK in 2013 and a further trial will take place in 2017.
PolyCAb has been developed for treatment of severe Clostridium difficile infections (“CDI”). It uses antibodies to bind to and neutralise the toxins the bacteria produce and has the potential to reduce recurrence and mortality rates amongst patients suffering from acute infections. Phase 1 clinical trials are expected to be completed in 2017.
MicroPharm is developing an orally administered immunotherapeutic product which will contain a combination of ovine and avian polyclonal antibodies directed against recombinant fragments of Toxin A and Toxin B for the treatment of mild to moderate severity primary and recurrent CDI.
In 2014 MicroPharm entered into a collaboration with Public Health England and the University of Oxford for the fast-track development of a treatment for Ebola Virus Disease. This development programme is ongoing.